- Obama to Send More Troops; Seeks Afghanistan Exit
- GM Removes CEO Henderson; Whitacre is Interim Chief
- Who Were the Biggest Winners And Losers This Year?
- Look Ahead: Markets Count Down to US Jobs Report
- GE, Comcast Complete Deal Over NBC Universal: Source
- US May Raise Rates Before Jobs Recover: Fed's Plosser
- Super Fantasy Christmas Gifts of 2009
- Cramer: Watch Tech Stocks Wednesday
- Stocks Likely Don't Need Santa to Keep Rally Going
- Unemployment to Peak at 10.5%: Moody's Economist
- 8 Stocks to Gain on Obama's Afghan Plan: Analysts
- BofA On Proposed Changes In The Housing Bailout Program
- The Future of The Media Landscape
- November Auto Sales Muddle Along
- Busch: What Obama Won't Say Tonight
- Stick with Equities—Avoid Emerging Markets: Laszlo Birinyi
- Pfizer Chomps On A Carrot
- Predictions 2010: Technology
MOST SHARED
- GE, Comcast Complete Deal Over NBC Universal: Source
- Keeping America Great
- Kohlberg Kravis Bidding for Morgan Stanley's CICC Stake
- Australia Parliament Rejects Carbon Trade Laws
- Toyota Takes Lead Position in Canada in November
- New Incentive To Improve... Your Home, That Is!
- Hyundai's US Auto Sales Jump 46% in November
- Trump: Time to Force Banks to Start Lending
Text Size 
A new study shows lowering cholesterol could increase the risk of cancer.
The Journal of the American College of Cardiology reports that researchers observed as much as triple the incidence of cancer among patients who lowered their bad or LDL cholesterol using the popular drugs known as statins. The rate, the study says, was especially high among patients with cholesterol levels below 160.
But they don't know if the cancer was caused by the drug, the low cholesterol or happenstance. The doctors who did the study say the heart benefits of statins still outweigh the risk of cancer and that patients should not stop taking their medication.
Researchers looked at the results of clinical trials involving more than 75,000 people who took statins. They're the
biggest segment of the drug industry accounting for $18 billion in sales in 2006, according to Verispan, which monitors prescriptions.
Pfizer's [PFE
Loading...
()
] Lipitor, Merck [MRK
Loading...
()
] and Schering-Plough's [SGP
Loading...
()
] Vytorin and AstraZeneca's [AZN
Loading...
()
] Crestor are among the top-selling brand-name statins.
The editor of JACC says the staff debated for three weeks whether to publish this study, but in the end decided that "these findings could not be ignored, that they did warrant further investigation, and that they should be aired in public."
Pfizer, which makes the world's top-selling statin, Lipitor, called the JACC study limited. The company said similar, larger analyses have shown no increased risk of cancer on the drug and that a company-sponsored clinical trial of 10,000 patients also showed no increased risk of cancer death.
Pfizer also said that the JACC study indicates no causal relationship between statins and cancer.
Print
Email
- Will the Fed raise rates? Will the dollar continue its slide? CNBC experts weigh in on the year ahead.
- Goldman Sachs has forbidden employees from gathering in private holiday parties of 12 or more.
- Do you have what it takes to run your own business? Ask yourself these questions.
- Heavily armed pirates in Somalia have set up a sort of stock exhange to fund their hijackings.
- Since its launch in 1998, Google has become a primary force on the Internet. How much do you know about the company?
- A famed author has written all his work on an old typewriter that is now up for auction. The NYT reports.
Data is a real-time snapshot *Data is delayed at least 15 minutes